ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Idarubicin: Drug information

Idarubicin: Drug information
(For additional information see "Idarubicin: Patient drug information" and see "Idarubicin: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Extravasation:

Idarubicin should be given slowly into a freely flowing intravenous infusion; it must never be given intramuscularly or subcutaneously. Severe local tissue necrosis can occur if there is extravasation during administration.

Cardiomyopathy:

As is the case with other anthracyclines, the use of idarubicin can cause myocardial toxicity leading to congestive heart failure. Cardiac toxicity is more common in patients who have received prior anthracyclines or who have preexisting cardiac disease.

Bone marrow suppression:

As is usual with antileukemic agents, severe myelosuppression occurs when idarubicin is used at effective therapeutic doses.

Experienced physician:

It is recommended that idarubicin be administered only under the supervision of a physician who is experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection.

Hepatic impairment:

Dosage should be reduced in patients with impaired hepatic function.

Renal impairment:

Dosage should be reduced in patients with impaired renal function.

Brand Names: US
  • Idamycin PFS
Pharmacologic Category
  • Antineoplastic Agent, Anthracycline;
  • Antineoplastic Agent, Topoisomerase II Inhibitor
Dosing: Adult

Actively manage modifiable cardiac risk factors (smoking, hypertension, diabetes, dyslipidemia, obesity) before initiating treatment (ASCO [Armenian 2017]). Idarubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (ASCO [Hesketh 2020]; MASCC/ESMO [Roila 2016]). Do not use idarubicin in patients with preexisting bone marrow suppression unless the benefit outweighs the risk. Ensure adequate hydration and consider use of antihyperuricemic prophylaxis in patients at risk for tumor lysis syndrome. Control systemic infections prior to idarubicin initiation.

Acute lymphoblastic leukemia, recurrent or refractory, salvage therapy

Acute lymphoblastic leukemia, recurrent or refractory, salvage therapy (off-label use): Induction: IV: 40 mg/m2 on day 3 (in combination with cytarabine, intrathecal methotrexate, and granulocyte-colony stimulating factor) for 1 cycle (Weiss 2002).

Acute myeloid leukemia

Acute myeloid leukemia :

Induction: IV: 12 mg/m2 on days 1 to 3 (in combination with cytarabine) for 1 cycle (Ohtake 2011; Pautas 2010); a second induction cycle may be administered after 3 to 4 weeks if necessary (Ohtake 2011).

Consolidation: IV: 12 mg/m2 on day 1 of cycle 1 (in combination with cytarabine) and 12 mg/m2 on days 1 and 2 of cycle 2 (in combination with cytarabine) (Pautas 2010).

Acute myeloid leukemia, poor-risk disease (off-label dosing): Induction: FLAG-IDA regimen: IV: 8 mg/m2 on days 4 to 6 (in combination with fludarabine, cytarabine, and granulocyte-colony stimulating factor) for 2 cycles (Burnett 2013).

Acute myeloid leukemia, relapsed/refractory (off-label dosing): FLAG-IDA regimen: IV: 10 mg/m2 on days 1 to 3 (in combination with fludarabine, cytarabine, and filgrastim); a second course may be given for consolidation upon hematologic recovery (Parker 1997).

Acute promyelocytic leukemia

Acute promyelocytic leukemia:

LPA 2005 regimen (high-risk patients):

Induction (all patients): IV: 12 mg/m2/day on days 2, 4, 6, and 8 (day 8 dose was omitted in patients >70 years of age) in combination with ATRA (tretinoin) (Sanz 2010).

Consolidation (patients ≤60 years of age): IV: 5 mg/m2/day for 4 days in consolidation cycle 1 and 12 mg/m2/day for 1 day in consolidation cycle 3 (in combination with ATRA [tretinoin] and cytarabine) (Sanz 2010).

APML4 protocol (Iland 2012): Induction (age-adjusted dosing):

Age <60 years of age: IV: 12 mg/m2/day on days 2, 4, 6, and 8 (in combination with ATRA [tretinoin] and arsenic trioxide).

Age 61 to 70 years: IV: 9 mg/m2/day on days 2, 4, 6, and 8 (in combination with ATRA [tretinoin] and arsenic trioxide).

Age >70 years of age: IV: 6 mg/m2/day on days 2, 4, 6, and 8 (in combination with ATRA [tretinoin] and arsenic trioxide).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; however, it does recommend that dosage reductions be made. Patients with Scr ≥2 mg/dL did not receive treatment in many clinical trials.

The following adjustments have been recommended (Krens 2019):

GFR ≥30 mL/minute: No dosage adjustment is necessary.

GFR <30 mL/minute: Consider administering 67% of original dose.

Hemodialysis: Consider administering 67% of original dose.

Dosing: Hepatic Impairment: Adult

Bilirubin 2.6 to 5 mg/dL: Administer 50% of dose (Krens 2019).

Bilirubin >5 mg/dL: Avoid use (Krens 2019).

Dosing: Obesity: Adult

American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m2: Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI <30 kg/m2; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (ASCO [Griggs 2021]).

Dosing: Adjustment for Toxicity: Adult

Manufacturer labeling: If patients experience severe mucositis during the first induction cycle, delay administration of the second cycle until mucositis has resolved; consider reducing the dose by 25% for subsequent cycles. In studies, if severe myelosuppression occurred, subsequent courses were administered with a 25% dose reduction.

Cardiotoxicity: Consider dexrazoxane (if appropriate) to reduce cardiac toxicity in patients who have received a high cumulative dose of anthracycline therapy (ESC [Lyon 2022]).

Asymptomatic cardiac dysfunction : Consider initiating heart failure medications (eg, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and/or beta blockers) in patients with asymptomatic (stage B) heart disease (ASCO [Armenian 2017]; ESC [Lyon 2022]).

Mild cardiac dysfunction: Continue treatment with close cardiovascular monitoring (ESC [Lyon 2022]).

Moderate or severe cardiac dysfunction: Interrupt treatment and utilize a multidisciplinary approach when deciding if/when to restart. Initiation of heart failure medications is recommended (ESC [Lyon 2022]).

Symptomatic cardiac dysfunction: Initiate heart failure medications (ESC [Lyon 2022]).

Mild cardiac dysfunction: Consider a multidisciplinary approach for decisions regarding treatment interruption versus continuation (ESC [Lyon 2022]).

Moderate cardiac dysfunction: Interrupt treatment; consider a multidisciplinary approach for decisions regarding treatment reinitiation (ESC [Lyon 2022]).

Severe cardiac dysfunction: Discontinue anthracycline therapy (ESC [Lyon 2022]).

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Idarubicin: Pediatric drug information")

Note: Dose, frequency, number of doses, and start date may vary by protocol and/or treatment phase; refer to specific protocol. In general, idarubicin use in pediatric patients is rare and has been replaced by newer agents and protocols. Idarubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (POGO [Dupuis 2011]).

Acute myeloid leukemia

Acute myeloid leukemia (AML): Limited data available: Infants, Children, and Adolescents:

New diagnosis (CCG-2961) (Lange 2008):

Induction: IV: IdaDCTER: Idarubicin 5 mg/m2/dose daily for 4 days on days 0 to 3 in combination with cytarabine, etoposide, thioguanine, and dexamethasone.

Consolidation: IV:

IdaDCTER: Idarubicin 5 mg/m2/dose daily for 4 days on days 0 to 3 in combination with cytarabine, etoposide, thioguanine, and dexamethasone.

OR

Idarubicin 12 mg/m2/dose daily for 3 days on days 0 to 2 in combination with fludarabine and cytarabine.

Relapsed/refractory: IV: Children and Adolescents: 12 mg/m2 once daily for 3 days in combination with fludarabine and cytarabine (Dinndorf 1997; Leahey 1997).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no specific dosage adjustments provided in the manufacturer's labeling; however, it does recommend that dosage reductions be made. Adult patients with Scr ≥2 mg/dL did not receive treatment in many clinical trials. The following adjustments have also been recommended (Aronoff 2007):

Infants, Children, and Adolescents:

GFR >50 mL/minute/1.73 m2: No adjustment necessary.

GFR ≤50 mL/minute/1.73 m2: Administer 75% of dose.

Intermittent hemodialysis: Administer 75% of dose.

Peritoneal dialysis (PD): Administer 75% of dose.

Continuous renal replacement therapy (CRRT): Administer 75% of dose.

Dosing: Hepatic Impairment: Pediatric

There are no specific dosage adjustments provided in the manufacturer's labeling; however, it does recommend that dosage reductions be made. Based on experience in adult patients, avoid use if bilirubin is >5 mg/dL and dosage adjustment suggested if bilirubin is 2.6 to 5 mg/dL (Perry 2012).

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults and may include combination therapy.

>10%:

Cardiovascular: Cardiac disorder (16%)

Dermatologic: Alopecia (77%), dermatological reaction (46%, including bullous pemphigoid [palms and soles], skin rash, urticaria)

Gastrointestinal: Abdominal cramps (≤73%), diarrhea (≤73%; grade 4: <5%), nausea (≤82%; grade 4: <5%), stomatitis (50%; grade 4: <5%), vomiting (≤82%; grade 4: <5%)

Hematologic & oncologic: Hemorrhage (63%)

Infection: Infection (95%)

Nervous system: Headache (20%), mental status changes (41%)

Respiratory: Pulmonary disease (39%)

Miscellaneous: Fever (26%)

1% to 10%:

Nervous system: Cerebellar disorder (4%), peripheral neuropathy (7%), seizure (4%)

Respiratory: Pulmonary hypersensitivity reaction (2%)

Frequency not defined:

Hematologic & oncologic: Bone marrow depression

Miscellaneous: Radiation recall phenomenon

Postmarketing:

Cardiovascular: Acute myocardial infarction, cardiac arrhythmia (including atrial fibrillation), cardiomyopathy (Ahmed 2019), chest pain, decreased left ventricular ejection fraction, heart failure

Gastrointestinal: Enterocolitis (with perforation)

Local: Urticaria at injection site

Contraindications

There are no contraindications listed in the manufacturer's US labeling.

Canadian labeling: Additional contraindications (not in the US labeling): Hypersensitivity to idarubicin, any component of the formulation, or to other anthracyclines or anthracenediones; uncontrolled infections; history of severe heart disease, recent myocardial infarction, severe myocardial insufficiency, severe arrhythmia; previous therapy with maximum cumulative doses of idarubicin, doxorubicin, daunorubicin, epirubicin, or other anthracycline and anthracenediones; severe persistent drug-induced myelosuppression; severe hepatic impairment; severe renal impairment

Warnings/Precautions

Concerns related to adverse effects:

• Bone marrow suppression: Severe myelosuppression occurs when idarubicin is used at effective therapeutic doses. Patients are at risk of developing infection and bleeding due to neutropenia and thrombocytopenia, respectively (may be fatal).

• Cardiomyopathy: Idarubicin may cause myocardial toxicity leading to heart failure. Cardiotoxicity is more common in patients who have previously received anthracyclines or have preexisting cardiac disease. The risk of myocardial toxicity is also increased in patients with concomitant or prior mediastinal/pericardial irradiation, patients with anemia, bone marrow depression, infections, leukemic pericarditis, or myocarditis. Patients with active or dormant cardiovascular disease, concurrent administration of cardiotoxic drugs (eg, trastuzumab, cyclophosphamide, paclitaxel), prior therapy with other anthracyclines or anthracenediones are also at increased risk for cardiotoxicity. Potentially fatal heart failure, acute arrhythmias (may be life-threatening) or other cardiomyopathies may also occur. Regular monitoring of left ventricular ejection fraction (LVEF) is recommended, especially in patients with cardiac risk factors or impaired cardiac function. The half-life of other cardiotoxic agents must be considered. Avoid the use of anthracycline-based therapy for at least 5 half-lives after discontinuation of the cardiotoxic agent, and specifically avoid idarubicin for up to 7 months after discontinuation of trastuzumab.

According to ASCO guidelines (ASCO [Armenian 2017]), the risk of cardiac dysfunction is increased with high-dose anthracycline therapy (eg, equivalent to doxorubicin ≥250 mg/m2); high-dose radiotherapy (≥30 Gy) with the heart in the treatment field; lower-dose anthracyclines (eg, equivalent to doxorubicin <250 mg/m2) in combination with lower-dose radiotherapy (<30 Gy) with the heart in the treatment field; lower-dose anthracyclines AND any of the following risk factors: ≥2 cardiovascular risk factors (including smoking, hypertension, diabetes, dyslipidemia, and obesity) during or after completion of therapy or ≥60 years of age at cancer treatment, or compromised cardiac function (eg, borderline low LVEF [50% to 55%], history of MI, moderate or higher valvular heart disease) before or during treatment; treatment with lower-dose anthracycline followed by trastuzumab (sequential therapy); other risk factors for anthracycline-induced cardiotoxicity include ≥60 years of age at time of treatment and 2 or more cardiovascular risk factors (smoking, hypertension, diabetes, dyslipidemia, or obesity) during or after treatment.

• Extravasation: Vesicant; may cause severe local tissue necrosis if extravasation occurs. For IV administration only; not for IM or SUBQ administration. Administer through a freely flowing IV infusion line preferably into a large vein. Ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.

• GI toxicity: Nausea/vomiting, mucositis, abdominal pain, and diarrhea commonly occur, although are severe in a small percentage of patients. Severe enterocolitis with perforation has been reported rarely (risk of perforation may be increased by instrumental intervention); consider the possibility of perforation in patients who develop severe abdominal pain and evaluate/manage appropriately.

• Hyperuricemia: Rapid lysis of leukemic cells may lead to hyperuricemia.

Special populations:

• Older adult: Patients >60 years of age who were undergoing induction therapy experienced heart failure, serious arrhythmias, chest pain, MI, and asymptomatic declines in LVEF more frequently than younger patients.

• Pediatrics: A panel from the American Society of Pediatric Hematology/Oncology (ASPHO) and International Society of Pediatric Oncology (SIOP) recommends in favor of an anthracycline infusion duration of at least 1 hour in pediatric patients to reduce the potential for cardiotoxicity (ASPHO/SIOP [Loeffen 2017]). However, extravasation risks should also be minimized and the protocol infusion duration specified in a protocol should be followed, particularly if the patient is receiving dexrazoxane as a cardioprotectant.

Other warnings/precautions:

• Experienced provider: Administer under the supervision of a provider experienced in leukemia and cancer chemotherapy, with capability to respond rapidly in the event of severe hemorrhagic conditions and/or overwhelming infection.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous, as hydrochloride [preservative free]:

Idamycin PFS: 5 mg/5 mL (5 mL); 10 mg/10 mL (10 mL); 20 mg/20 mL (20 mL)

Generic: 5 mg/5 mL (5 mL); 10 mg/10 mL (10 mL); 20 mg/20 mL (20 mL)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Idamycin PFS Intravenous)

5 mg/5 mL (per mL): $12.94

10 mg/10 mL (per mL): $12.93

20 mg/20 mL (per mL): $12.42

Solution (IDArubicin HCl Intravenous)

5 mg/5 mL (per mL): $7.20 - $18.54

10 mg/10 mL (per mL): $7.20 - $16.07

20 mg/20 mL (per mL): $7.20 - $13.78

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Generic: 1 mg/mL (5 mL, 10 mL, 20 mL)

Administration: Adult

Idarubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (ASCO [Hesketh 2020]; MASCC/ESMO [Roila 2016]).

IV: For IV administration only. Do not administer IM or SubQ; administer as slow injection over 10 to 15 minutes into a free-flowing IV solution of NS or D5W.

Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.

Extravasation management: If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity. Initiate antidote (dexrazoxane or dimethyl sulfate [DMSO]). Apply dry cold compresses for 20 minutes 4 times daily for 1 to 2 days (ESMO/EONS [Pérez Fidalgo 2012]); withhold cooling beginning 15 minutes before dexrazoxane infusion; continue withholding cooling until 15 minutes after infusion is completed. Topical DMSO should not be administered in combination with dexrazoxane; may lessen dexrazoxane efficacy.

Dexrazoxane: 1,000 mg/m2 (maximum dose: 2,000 mg) IV (administer in a large vein remote from site of extravasation) over 1 to 2 hours days 1 and 2, then 500 mg/m2 (maximum dose: 1,000 mg) IV over 1 to 2 hours day 3; begin within 6 hours of extravasation. Day 2 and day 3 doses should be administered at approximately the same time (±3 hours) as the dose on day 1 (ESMO/EONS [Pérez Fidalgo 2012]; Mouridsen 2007). Note: Reduce dexrazoxane dose by 50% in patients with moderate to severe renal impairment (CrCl <40 mL/minute).

DMSO: Apply topically to a region covering twice the affected area every 8 hours for 7 days; begin within 10 minutes of extravasation; do not cover with a dressing (ESMO/EONS [Pérez Fidalgo 2012]).

Administration: Pediatric

Idarubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (POGO [Dupuis 2011]).

For IV administration only. Do not administer IM or SubQ; administer as slow push over 3 to 5 minutes, preferably into the side of a freely-running saline or dextrose infusion or as intermittent infusion over 10 to 15 minutes into a free-flowing IV solution of NS or D5W.

Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity. Initiate antidote (dimethyl sulfate [DMSO] or dexrazoxane [adult]) (see Management of Drug Extravasations for more details). Apply dry cold compresses for 20 minutes 4 times daily for 1 to 2 days (ESMO/EONS [Pérez Fidalgo 2012]); withhold cooling beginning 15 minutes before dexrazoxane infusion; continue withholding cooling until 15 minutes after infusion is completed. Topical DMSO should not be administered in combination with dexrazoxane; may lessen dexrazoxane efficacy.

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2016 [group 1]).

Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).

Use: Labeled Indications

Acute myeloid leukemia: Treatment of acute myeloid leukemia in adults (in combination with other approved chemotherapy agents).

Use: Off-Label: Adult

Acute lymphoblastic leukemia, recurrent or refractory, salvage therapy

Medication Safety Issues
Sound-alike/look-alike issues:

IDArubicin may be confused with DAUNOrubicin, daunorubicin/cytarabine, DOXOrubicin, epiRUBicin, idaruCIZUmab, idelalisib, valrubicin

Idamycin PFS may be confused with Adriamycin

High alert medication:

This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.

Metabolism/Transport Effects

Substrate of P-glycoprotein/ABCB1 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk C: Monitor therapy

Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Ado-Trastuzumab Emtansine: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with ado-trastuzumab emtansine should avoid anthracycline-based therapy for up to 7 months after stopping ado-trastuzumab emtansine. Monitor closely for cardiac dysfunction in patients receiving this combination. Risk D: Consider therapy modification

Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. Risk C: Monitor therapy

Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. Risk X: Avoid combination

BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. Risk X: Avoid combination

Bevacizumab: May enhance the cardiotoxic effect of Anthracyclines. Risk X: Avoid combination

Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. Risk C: Monitor therapy

Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). Risk X: Avoid combination

Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents. Risk C: Monitor therapy

Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). Risk X: Avoid combination

Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk X: Avoid combination

Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. Risk X: Avoid combination

CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. Risk C: Monitor therapy

Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test. Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results. Risk D: Consider therapy modification

COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector). Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters). Risk D: Consider therapy modification

COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). Risk C: Monitor therapy

COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA). Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details. Risk D: Consider therapy modification

COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). Risk C: Monitor therapy

COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). Risk C: Monitor therapy

CycloPHOSphamide: May enhance the cardiotoxic effect of Anthracyclines. Risk C: Monitor therapy

Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely. Risk D: Consider therapy modification

Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). Risk X: Avoid combination

Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections. Risk D: Consider therapy modification

Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased Risk X: Avoid combination

Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Fam-Trastuzumab Deruxtecan: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with fam-trastuzumab deruxtecan should avoid anthracycline-based therapy for up to 7 months after stopping fam-trastuzumab deruxtecan. Monitor closely for cardiac dysfunction in patients receiving this combination. Risk D: Consider therapy modification

Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. Risk X: Avoid combination

Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. Risk C: Monitor therapy

Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored. Risk D: Consider therapy modification

Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide. Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy. Risk D: Consider therapy modification

Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim. Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy. Risk D: Consider therapy modification

Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim. Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy. Risk D: Consider therapy modification

Margetuximab: Anthracyclines may enhance the adverse/toxic effect of Margetuximab. Specifically, the risk of cardiac dysfunction may be increased. Management: Avoid anthracycline-based therapy for up to 4 months after discontinuing margetuximab due to an increased risk of cardiac dysfunction. If anthracyclines must be used with margetuximab monitor cardiac function closely. Risk D: Consider therapy modification

Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Risk X: Avoid combination

Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. Risk X: Avoid combination

Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. Risk X: Avoid combination

Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. Risk C: Monitor therapy

Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. Risk C: Monitor therapy

Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. Risk C: Monitor therapy

Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy. Risk D: Consider therapy modification

Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. Risk C: Monitor therapy

Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. Risk C: Monitor therapy

Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Risk X: Avoid combination

Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider therapy modification

Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk C: Monitor therapy

Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine. Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine. Risk D: Consider therapy modification

Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. Risk X: Avoid combination

Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b. Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects. Risk D: Consider therapy modification

Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). Risk X: Avoid combination

Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T. Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy. Risk D: Consider therapy modification

Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk C: Monitor therapy

Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). Risk X: Avoid combination

Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. Risk X: Avoid combination

Taxane Derivatives: May enhance the adverse/toxic effect of Anthracyclines. Taxane Derivatives may increase the serum concentration of Anthracyclines. Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue. Management: Consider separating doxorubicin and paclitaxel administration by as much time as possible, using liposomal doxorubicin or epirubicin instead of doxorubicin, or using docetaxel instead of paclitaxel. Monitor closely for cardiovascular and other toxicities. Risk D: Consider therapy modification

Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. Risk X: Avoid combination

Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. Risk X: Avoid combination

Trastuzumab: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with trastuzumab should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab. Monitor closely for cardiac dysfunction in patients receiving anthracyclines with trastuzumab. Risk D: Consider therapy modification

Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. Risk X: Avoid combination

Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. Risk C: Monitor therapy

Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. Risk X: Avoid combination

Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete. Risk D: Consider therapy modification

Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. Risk X: Avoid combination

Reproductive Considerations

Evaluate pregnancy status prior to use in patients who could become pregnant; pregnancy should be avoided during treatment with idarubicin.

Patients who could become pregnant should use effective contraception during therapy and for 6.5 months after the last idarubicin dose. Patients with partners who could become pregnant should also use effective contraception during therapy and for 3.5 months after the last dose of idarubicin.

Idarubicin is associated with an intermediate risk of azoospermia and infertility in males (ESMO [Lambertini 2020]). Fertility preservation should be considered for both females and males prior to treatment with idarubicin and/or seek genetic counseling after treatment. Recommendations are available for fertility preservation in adult patients treated with anticancer agents (ASCO [Oktay 2018]).

Pregnancy Considerations

Idarubicin is more lipophilic than other anthracycline antineoplastic agents, therefore placental transfer is more likely (BSH [Ali 2015]; ELN [Döhner 2010]). Neonatal neutropenia, cardiac cardiomyopathy, and an increased risk of other fetal complications may be associated with in utero exposure to idarubicin (BSH [Ali 2015]; Chang 2015; Lishner 2016; Thomas 2015). Fetal fatality has been reported following maternal use during the second trimester.

Available guidelines recommend use of an anthracycline agent other than idarubicin (in combination with cytarabine) for induction treatment in acute myeloid leukemia (AML) in pregnant patients, and treatment should only be in the second and third trimester (BSH [Ali 2015]; ESMO [Peccatori 2013]; Lishner 2016). The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy; the guidelines recommend referral to a facility with expertise in cancer during pregnancy and a multidisciplinary team (obstetrician, neonatologist, oncology team) is encouraged (ESMO [Peccatori 2013]).

A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (1-877-635-4499).

Breastfeeding Considerations

It is not known if idarubicin is present in breast milk.

Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding should be discontinued prior to idarubicin therapy; patients should not breastfeed during therapy and for 14 days after the last idarubicin dose.

Monitoring Parameters

Monitor cumulative (lifetime) anthracycline/idarubicin dose. CBC with differential and platelet count (frequently), cardiac function (LVEF; prior and during treatment), serum electrolytes, renal function (serum creatinine; prior to and during treatment), uric acid, liver function (ALT, AST, bilirubin; prior to and during treatment). Evaluate pregnancy status prior to use in patients who could become pregnant. Monitor infusion site for signs of extravasation; monitor for GI toxicity and infection.

Additional cardiovascular monitoring (ASCO [Armenian 2017], ESC [Lyon 2022]): Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking. Obtain echocardiogram (transthoracic preferred, perform at baseline and 12 months after therapy completion for all patients; in addition, perform every 2 cycles and within 3 months after therapy completion for high- or very high-risk patients). Cardiac biomarkers (troponin and natriuretic peptide at baseline for high and very high-risk patients [may consider for low- and moderate-risk]; also prior to each cycle during anthracycline treatment and at 3 and 12 months after therapy completion for high- and very high-risk patients). In patients who develop signs/symptoms of cardiac dysfunction during therapy, an echocardiogram is recommended for diagnostic workup; if echocardiogram is not available or feasible, a cardiac MRI (preferred) or MUGA scan may be utilized; obtain serum cardiac biomarkers. Refer to a cardiologist when clinically indicated. Consider cardioprotectants (eg, dexrazoxane) or continuous infusions in patients who are likely to receive high-dose anthracycline therapy.

The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.

Mechanism of Action

Idarubicin inhibits DNA and RNA synthesis by intercalation between DNA base pairs and by steric obstruction. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: Vdss: 1,500 L/m2 (Robert 1993); extensive tissue binding; CSF

Protein binding: 94% (idarubicinol) to 97% (idarubicin)

Metabolism: Hepatic to idarubicinol (active metabolite)

Half-life elimination:

Children: Children ≥1 year of age and adolescents: 17.6 ± 6.8 hours (range: 8.3 to 29.6 hours) (Reid 1990)

Adults: Adults: 22 hours (range: 4 to 48 hours); >45 hours (idarubicinol)

Excretion: Primarily biliary; urine (8 to 10% as idarubicinol, ~2% to 5% as unchanged drug [Robert 1993])

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: The disposition may be affected in patients with renal impairment.

Hepatic function impairment: Possible impaired metabolism leading to higher systemic concentrations in patients with moderate and severe impairment; disposition may also be affected.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Zavedos;
  • (AR) Argentina: Idarrubicina dosa | Idarubicina gp pharm | Idarubicina ima | Idarubicina microsules | Zavedos;
  • (AT) Austria: Idarubicin accord | Zavedos;
  • (AU) Australia: Idarubicin Ebewe | Zavedos;
  • (BE) Belgium: Idarubicin Ebewe | Idarubin | Zavedos;
  • (BG) Bulgaria: Zavedos;
  • (BR) Brazil: Evomid | Ida | Zavedos;
  • (CH) Switzerland: Idarubicin Cancernova | Zavedos;
  • (CL) Chile: Idarubicina clorhidrato | Zavedos;
  • (CN) China: Ai nuo ning | An bi jian | Shan wei da | Zavedos;
  • (CO) Colombia: Idaralen | Idarubicina | Idarubicina clorhidrato | Zavedos;
  • (CZ) Czech Republic: Idarubicin accord | Zavedos;
  • (DE) Germany: Idarubicin accord | Idarubicin hexal | Zavedos;
  • (DO) Dominican Republic: Zavedos;
  • (EC) Ecuador: Idarubicina | Idarubicina clorhidrato | Zavedos;
  • (EE) Estonia: Idarubicin accord | Zavedos;
  • (EG) Egypt: Zavedos;
  • (ES) Spain: Idarubicina sandoz | Zavedos;
  • (FI) Finland: Idarubicin accord | Zavedos;
  • (FR) France: Idarubicine Mylan | Zavedos;
  • (GB) United Kingdom: Idarubicin | Zavedos;
  • (GR) Greece: Zavedos;
  • (HK) Hong Kong: Zavedos;
  • (HU) Hungary: Zavedos;
  • (ID) Indonesia: Zavedos;
  • (IE) Ireland: Zavedos;
  • (IN) India: Zavedos;
  • (IT) Italy: Idarubicina mylan generics | Idarubicina sandoz | Zavedos;
  • (JO) Jordan: Zavedos;
  • (JP) Japan: Idamycin;
  • (KR) Korea, Republic of: Boryung idarubicin hcl | Idaralem | Idaru | Zavedos | Zavel | Zaverucin;
  • (LB) Lebanon: Zavedos;
  • (LT) Lithuania: Idarubicin | Zavedos;
  • (LU) Luxembourg: Zavedos;
  • (LV) Latvia: Idarubicin | Zanedos | Zavedos;
  • (MA) Morocco: Zavedos;
  • (MX) Mexico: Idacrybin | Idamycin | Idaralem | Ondarubin;
  • (MY) Malaysia: Zavedos;
  • (NL) Netherlands: Idarubicine hcl sandoz;
  • (NO) Norway: Idarubicin accord | Zavedos;
  • (NZ) New Zealand: Idarubicin | Zavedos;
  • (PE) Peru: Zavedos;
  • (PH) Philippines: Zavedos;
  • (PK) Pakistan: Zavedos;
  • (PL) Poland: Idarubicin teva | Zavedos;
  • (PR) Puerto Rico: Idamycin | Idamycin PFS | Idarubicin;
  • (PT) Portugal: Idarrubicina Accord | Idarrubicina Azevedos | Idarrubicina Hikma | Idarrubicina Sandoz | Idarrubicina Teva | Zavedos;
  • (PY) Paraguay: Idarubicina clorhidrato;
  • (QA) Qatar: Zavedos;
  • (RO) Romania: Idarubicina accord | Zavedos;
  • (RU) Russian Federation: Idarubicin | Rubide | Zavedos;
  • (SA) Saudi Arabia: Zavedose;
  • (SE) Sweden: Idarubicin accord | Zavedos;
  • (SG) Singapore: Zavedos;
  • (SI) Slovenia: Zavedos;
  • (SK) Slovakia: Zavedos;
  • (TH) Thailand: Zavedos | Zavedos cs;
  • (TN) Tunisia: Idanthra;
  • (TR) Turkey: Idamen | Idarub | Zadoss | Zavedos;
  • (TW) Taiwan: Zavedos;
  • (UA) Ukraine: Zavedos;
  • (UY) Uruguay: Idarubicina FU;
  • (ZA) South Africa: Zavedos
  1. <800> Hazardous Drugs—Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.
  2. Ahmed Z, Davaro E, Batanian J, Verma N. First-dose idarubicin cardiomyopathy: a case of new heart failure after induction chemotherapy for acute myeloid leukaemia. BMJ Case Rep. 2019;12(5):e228149. doi:10.1136/bcr-2018-228149 [PubMed 31101747]
  3. Ali S, Jones GL, Culligan DJ, et al; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. Br J Haematol. 2015;170(4):487-495. doi:10.1111/bjh.13554 [PubMed 26081614]
  4. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893-911. doi: 10.1200/JCO.2016.70.5400. [PubMed 27918725]
  5. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 100, 172.
  6. Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31(27):3360-3368. doi:10.1200/JCO.2012.47.4874 [PubMed 23940227]
  7. Chang A, Patel S. Treatment of acute myeloid leukemia during pregnancy. Ann Pharmacother. 2015;49(1):48-68. doi:10.1177/1060028014552516 [PubMed 25258419]
  8. Dinndorf PA, Avramis VI, Wiersma S, et al. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. J Clin Oncol. 1997;15(8):2780-2785. [PubMed 9256119]
  9. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474. doi:10.1182/blood-2009-07-235358 [PubMed 19880497]
  10. Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2011;57(2):191-198. [PubMed 21465637]
  11. Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005;23(30):7685-7696. [PubMed 16234530]
  12. Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. J Clin Oncol. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471 [PubMed 33939491]
  13. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296 [PubMed 32658626]
  14. Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757 [PubMed 32716741]
  15. Idamycin (idarubicin hydrochloride) [prescribing information]. New York, NY: Pfizer; May 2022.
  16. Idamycin PFS (idarubicin hydrochloride) [prescribing information]. New York, NY: Pfizer; April 2022.
  17. Idarubicin hydrochloride [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; September 2022.
  18. Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120(8):1570-1580. [PubMed 22715121]
  19. Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7 [PubMed 30942181]
  20. Lambertini M, Peccatori FA, Demeestere I, et al; ESMO Guidelines Committee. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2020;31(12):1664-1678. doi:10.1016/j.annonc.2020.09.006 [PubMed 32976936]
  21. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 2008;111(3):1044-1053. [PubMed 18000167]
  22. Leahey A, Kelly K, Rorke LB, et al. A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F-ara-A) and cytarabine (ara-C) for refractory or recurrent pediatric acute myeloid leukemia (AML). J Pediatr Hematol Oncol. 1997;19(4):304-308. [PubMed 9256828]
  23. Lishner M, Avivi I, Apperley JF, et al. Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. J Clin Oncol. 2016;34(5):501-508. doi:10.1200/JCO.2015.62.4445 [PubMed 26628463]
  24. Loeffen EAH, van Dalen EC, Mulder RL, et al. The duration of anthracycline infusion should be at least one hour in children with cancer: A clinical practice guideline [published online October 27, 2017]. Pediatr Blood Cancer. 2018;65(2). doi: 10.1002/pbc.26867. [PubMed 29077260]
  25. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244 [PubMed 36017568]
  26. Morgan C, Tillett T, Braybrooke J, et al. Management of uncommon chemotherapy-induced emergencie. Lancet Oncol. 2011;12(8):806-814. [PubMed 21276754]
  27. Mouridsen HT, Langer SW, Buter J, et al. Treatment of anthracycline extravasation with Savene (Dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol. 2007;18(3):546-550. [PubMed 17185744]
  28. Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 study. Blood. 2011;117(8):2358-2365. doi:10.1182/blood-2010-03-273243 [PubMed 20693429]
  29. Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994-2001. doi:10.1200/JCO.2018.78.1914 [PubMed 29620997]
  30. Parker JE, Pagliuca A, Mijovic A, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 1997;99(4):939-944. [PubMed 9432047]
  31. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol. 2010;28(5):808-814. doi:10.1200/JCO.2009.23.2652 [PubMed 20048183]
  32. Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl 6):vi160-170. doi: 10.1093/annonc/mdt199. [PubMed 23813932]
  33. Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):167-173. [PubMed 22997449]
  34. Perry MC. Chemotherapeutic Agents: Idarubicin in The Chemotherapy Source Book. 5th ed. Philadelphia, PA: 2012.
  35. Reid JM, Pendergrass TW, Krailo MD, et al, “Plasma Pharmacokinetics and Cerebrospinal Fluid Concentrations of Idarubicin and Idarubicinol in Pediatric Leukemia Patients: A Children's Cancer Study Group Report,” Cancer Res, 1990, 50(20):6525-8. [PubMed 2208112]
  36. Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet. 1993;24(4):275-288. [PubMed 8491056]
  37. Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119-v133. doi: 10.1093/annonc/mdw270 [PubMed 27664248]
  38. Sanz MA, Montesinos P, Rayon C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115(25):137-146. [PubMed 20393132]
  39. Thomas X. Acute myeloid leukemia in the pregnant patient. Eur J Haematol. 2015;95(2):124-136. doi:10.1111/ejh.12479 [PubMed 25409600]
  40. US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. https://www.cdc.gov/niosh/docs/2016-161/default.html. Updated September 2016. Accessed October 5, 2016.
  41. Weiss MA, Aliff TB, Tallman MS, et al. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer. 2002;95(3):581-587. doi:10.1002/cncr.10707 [PubMed 12209751]
Topic 8549 Version 301.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟